Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.201
-0.009 (-4.29%)
At close: Apr 28, 2026, 4:00 PM EDT
0.201
0.00 (0.00%)
After-hours: Apr 28, 2026, 5:43 PM EDT
Sangamo Therapeutics Stock Forecast
SGMO's stock price has decreased by -74.46% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Sangamo Therapeutics stock have an average target of 7.00, with a low estimate of 1.00 and a high estimate of 10. The average target predicts an increase of 3,382.59% from the current stock price of 0.20.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 10, 2026.
Analyst Ratings
The average analyst rating for Sangamo Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +4,875.12% | Feb 10, 2026 |
| Barclays | Barclays | Buy → Hold Downgrades $5 → $1 | Buy → Hold | Downgrades | $5 → $1 | +397.51% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +4,875.12% | Sep 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +4,875.12% | Jun 24, 2025 |
| Barclays | Barclays | Buy Maintains $9 → $5 | Buy | Maintains | $9 → $5 | +2,387.56% | May 14, 2025 |
Financial Forecast
Revenue This Year
81.93M
from 39.55M
Increased by 107.15%
Revenue Next Year
144.56M
from 81.93M
Increased by 76.44%
EPS This Year
-0.22
from -0.44
EPS Next Year
-0.07
from -0.22
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 119.7M | 274.7M | ||||||
| Avg | 81.9M | 144.6M | ||||||
| Low | 9.7M | 69.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 202.6% | 235.3% | ||||||
| Avg | 107.2% | 76.4% | ||||||
| Low | -75.5% | -15.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.07 | 0.11 | ||||||
| Avg | -0.22 | -0.07 | ||||||
| Low | -0.39 | -0.22 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.